Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286Business Wire • 12/12/22
Down 67.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Clovis (CLVS)Zacks Investment Research • 11/21/22
Clovis Oncology stock slides 75% after biotech warns it will run out of cash by January of 2023Market Watch • 11/09/22
Clovis Oncology: Looking Like An Acquisition Target After Recent Company UpdatesSeeking Alpha • 10/29/22
Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (rucaparib) at the 29th Annual Prostate Cancer Foundation Scientific RetreatBusiness Wire • 10/27/22
Will Clovis Oncology (CLVS) Report Negative Q3 Earnings? What You Should KnowZacks Investment Research • 10/26/22
Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM CongressBusiness Wire • 10/17/22
TRITON3 Phase 3 Trial of Rubraca® (rucaparib) Achieves Primary Endpoint in Men with Metastatic Castration-Resistant Prostate Cancer with BRCA or ATM MutationsBusiness Wire • 10/03/22